Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness (BIRCH)
COVID-19
About this trial
This is an interventional treatment trial for COVID-19
Eligibility Criteria
Key Inclusion Criteria: Willing and able to provide written informed consent. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed by PCR or an approved alternative assay (eg. Rapid Antigen Test) ≤ 5 days before randomization. Serologic tests will not be accepted. Initial onset of COVID-19 signs/symptoms ≤ 5 days before randomization. Not currently hospitalized or requiring hospitalization. Presence of ≥ 1 risk factor (if unvaccinated) or ≥ 2 risk factors (if vaccinated at any point) for progression to severe disease. Key Exclusion Criteria: Anticipated use of COVID-19 therapies during the current COVID-19 illness. Received any direct acting antiviral drug against SARS-CoV-2 for the treatment of COVID-19 < 28 days or < 5 half-lives, whichever is longer, before randomization. Anticipated need for hospitalization < 48 hours after randomization. New oxygen requirement < 24 hours before randomization. Decompensated cirrhosis (Child-Pugh class B or C) or acute liver injury/failure. Undergoing dialysis, or history of moderate to severe renal impairment. Pregnant or breastfeeding (nursing). Unwilling to use protocol-mandated birth control. Received an approved, authorized or investigational COVID-19 vaccine (including booster dose) <120 days before randomization. Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Sites / Locations
- Faculdade de Medicina da Universidade Federal de Minas Gerais
- L2iP Instituto de Pesquisas Clínicas
- Hospital da PUC Campinas - Centro de Pesquisa Sao Lucas
- Hospital do Rocio/ Maternidade e Cirurgia Nossa Senhora do Rocio
- Centro de Pesquisa NEIMPI - Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
- Centro de Pesquisa Clinica da Universidade Municipal de São Caetano do Sul (USCS)
- Faculdade de Medicina da Universidade Estadual Paulista-UNESP/HC da Faculdade de Medicina de Botucatu-HCFMB
- Multiprofile Hospital for Active Treatment Puls AD, Department of Internal Diseases
- Medical Center Asklepii OOD
- Specialìzed Hosp¡tal for Active Trealment of Pneumophthisiatric Diseases Haskovo EOOD, Department of pneumology and phthisiatry
- Medical Center Zdrave-1 OOD
- Diagnostic Consultative Center 1 - Lon EOOD
- Medical Center Hera EOOD, Montana
- Multiprofile Hospital for Active Treatment Dr. Stamen Iliev AD, Department of Pneumology Phthisiatrics
- Medical Center Medconsult Pleven OOD
- University Multiprofile Hospital for Active Treatment Sveta Marina - Pleven OOD, Clinic of Anesthesiology and lntensive Care
- Diagnostic Consultative Center Sveti Georgi EOOD
- MHAT Sveta Karidad EAD, First Department of Anesthesiology and Intensive Care
- Multiprofile Hospital for Active Treatment Sveti Panteleymon EOOD, First Department of Internal Diseases
- Multiprofile Hospital for Active Treatment Sv. Ivan Rilski - Razgrad AD, Department of pneumology and phthisiatry
- Medical Center Prolet EOOD
- Multiprofile Hospital for Active Treatment - Samokov EOOD, Department of Internal Diseases
- Medical Center Unimed EOOD
- Diagnostic and Consulting Center Aleksandrovska EOOD
- Medical Center Hera EOOD
- University Multiprofile Hospital for Active Treatment and Emergency Medicine ,,N. l. Pirogov" EAD,Clinic of lnternal Diseases
- Diagnostic Consultative Center XX - Sofia EOOD
- University Multiprofile Hospital for Active Treatment Sofiamed OOD, block 2, Department of lnfectious Diseases, COVID cabinet
- University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD, Infectious Diseases Clinic
- Medical Center Leo Clinic EOOD
- Medical Center Sanador M EOOD
- Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases-Vratsa EOOD, Department of Pneumology
- Hamilton Medical Research Group
- Dr. Anil K. Gupta Medicine Professional Corporation
- Vancouver ID Research and Care Centre Society
- FamilyMED s.r.o.
- Neocnice Nove Mesto Morave p.o. Infekcni oddeleni
- MEDISON, s.r.o.
- Hopital Gabriel Montpied
- Hopital St Joseph
- CHU de Montpellier-Hopital La Colombiere
- CHU Caremeau
- Hopital Pitie Salpetriere
- Hopital Saint Louis
- CH de Tourcoing
- Debreceni Egyetem Klinikai Kozpont
- Unita Operativa Di Malattie Infettive Ospedale San Raffaele S.r.l.
- Dipartimento di Malattie Infettive Ospedale Luigi Sacco ASST Fatebenefratelli Sacco
- SC Malattie Infettive ASST GOM Niguarda
- Azienda Universitaria Federico II - UOC Malattie Infettive
- Divisione di Malattie Infettive Azienda Ospedaliero Universitaria Pisana
- Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS - U.O.C. Malattie Infettive ad Alta Intensita di Cura
- IUHW Narita Hospital
- Okayama University Hospital
- Suita Municipal Hospital
- ChungNam National University Hospital
- Chonnam National University Hospital
- Chonnam National University Bitgoeul Hospital
- Seoul Medical Center
- Hallym University Kangdong Sacred Heart Hospital
- Korea University Guro Hospital
- Centro Regional de Infectologia del Norte de Mexico
- Panamerican Clinical Research Mexico S.A. de C.V.
- Neurociencias Estudios Clinicos S.C.
- PanAmerican Clinical Research Mexico S.A de C.V.
- EME RED Hospitalaria
- Clinstile, S.A. De C.V.
- Sociedad Administradora de Servicios de Salud, S.C.
- Kohler & Milstein Research S.A de C.V.
- Oaxaca Site Management Organization S.C.
- FAICIC S. de R.L. de C.V.
- ClinMedica Research
- Centrum Medyczne Pulawska Sp. z o.o
- Provita Poliklinika
- Centrum Badan Klinicznych JCI
- Ginemedica OVO 21
- ETG Lodz
- Hospital Senhora da Oliveira - Guimareas EPE
- Hospital CUF Descobertas
- Centro Hospitalar Universitario de Santo Antonio E.P.E
- Centro Hospitalar de Entre Douro e Vouga - Hospital de Sao Sebaststiao
- Hospital da Luz - Arrabida
- "Prof. Dr. Matei Bals" National Institute for Infectious Diseases
- County Hospital Caracal
- Sibiu Emergency Clinical County Hospital
- National University Hospital
- National Centre for Infectious Diseases, Tan Tock Seng Hospital
- Madibeng Centre for Research
- Clinresco Centres (Pty) Ltd
- Synapta Clinical Research Centre
- Perinatal HIV Research Unit (PHRU)
- Setshaba Research Centre
- Jongaie Research
- Global Clinical Trials
- Limpopo Clinical Research Initiative
- FCRN Clinical Trial Centre (Pty) Ltd
- Hospital Universitario A Coruña
- Hospital Universitario Virgen de Las Nieves.Recruiting
- Hospital General Universitario Dr. Balmis
- Hospital Universitari Germans Trias i Pujol
- Hospital del Mar
- CAP La Mina
- Hospital HM Nou Delfos
- Hospital Clinic de Barcelona
- Hospital Universitario de Bellvitge
- Hospital General Universitario De Elche
- Hospital Universitario Virgen del Rocio
- Hospital Universitario Infanta Leonor
- Hospital Clinico San Carlos
- Hospital Universitario 12 de Octubre
- Hospital Universitario La Paz
- Hospital Universitario Puerta de Hierro - MajadahondaRecruiting
- Hospital Costa Del Sol
- Hospital General Universitario Reina Sofia
- Hospital Universitario Son Espases
- Hospital Universitaro y Politecnico La Fe
- Hospital Clinico Universitario de Valladolid
- Hopitaux Universitaires de Geneve (HUG)
- Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
- Far Eastern Memorial Hospital
- China Medical University Hospital
- Chi Mei Medical Center
- National Taiwan University Hospital
- Tao-Yuan General Hospital
- Chang Gung Memorial Hospital (CGMH)
- Kaohsiung Veterans General Hospital
- Izmir Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital
- Cukurova University Medical Faculty Balcali Hospital
- Acibadem University School of Medicine Atakent Hospital
- Karadeniz Technical University Faculty of Medicine
- Ormeau Clinical Trials Limited
- Lakeside Healthcare
- CPS Research
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Obeldesivir
Placebo
Participants will receive obeldesivir 350 mg twice daily for 5 days.
Participants will receive placebo twice daily for 5 days.